182 related articles for article (PubMed ID: 15061983)
1. [To pay attention to histological study of benign prostatic hyperplasia].
Xia TL
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):360-3. PubMed ID: 15061983
[No Abstract] [Full Text] [Related]
2. [Benign prostatic diseases--differential diagnosis and therapy].
Zwergel T; Zwergel U
Urologe A; 1993 Jan; 32(1):W67-80. PubMed ID: 7680506
[No Abstract] [Full Text] [Related]
3. The prostate--a gland that does not age well.
Dille JR
Aviat Space Environ Med; 1994 Oct; 65(10 Pt 1):961-2. PubMed ID: 7530444
[No Abstract] [Full Text] [Related]
4. The natural history of benign prostatic hyperplasia.
Harv Mens Health Watch; 1998 Mar; 2(8):1-5. PubMed ID: 9516320
[No Abstract] [Full Text] [Related]
5. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
6. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
7. Prevention of benign prostatic hyperplasia disease.
Marks LS; Roehrborn CG; Andriole GL
J Urol; 2006 Oct; 176(4 Pt 1):1299-306. PubMed ID: 16952616
[TBL] [Abstract][Full Text] [Related]
8. Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: an autopsy study.
Stamatiou K; Alevizos A; Agapitos E; Sofras F
Prostate; 2006 Sep; 66(12):1319-28. PubMed ID: 16688747
[TBL] [Abstract][Full Text] [Related]
9. Benign prostatic hyperplasia: medical management considering sexual function and prostate cancer.
Finkelstein LH
J Am Osteopath Assoc; 2004 Feb; 104(2 Suppl 2):1 p preceding S1. PubMed ID: 15038395
[No Abstract] [Full Text] [Related]
10. Aggressive angiomyxoma of the prostate mimicking benign prostatic hyperplasia.
Bastian PJ; Fisang C; Schmidt ME; Biermann K; Textor J; Müller SC
Eur J Med Res; 2006 Apr; 11(4):167-9. PubMed ID: 16720282
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.
Hussein MR; Al-Assiri M; Musalam AO
Exp Mol Pathol; 2009 Apr; 86(2):108-13. PubMed ID: 19111537
[TBL] [Abstract][Full Text] [Related]
12. [Consideration of the guideline of diagnosis and treatment for benign prostate hyperplasia].
Zhang XH
Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(14):939-40. PubMed ID: 17961373
[No Abstract] [Full Text] [Related]
13. Hormones & you. Patient information page. Benign prostatic hyperplasia (enlarged prostate).
Hormone Foundation
J Clin Endocrinol Metab; 2005 Oct; 90(10):2 p preceding inside back cover. PubMed ID: 16231864
[No Abstract] [Full Text] [Related]
14. Role of fine needle aspiration cytology (FNAC) in the diagnosis of prostatic lesions with histologic correlation.
Saleh AF; Nahar Rahman AJ; Salam MA; Islam F
Bangladesh Med Res Counc Bull; 2005 Dec; 31(3):95-103. PubMed ID: 17549870
[TBL] [Abstract][Full Text] [Related]
15. [Treatment recommendations for benign prostate hypertrophy].
Suomen Urologiyhdistyksen hoitosuositusryhmä
Duodecim; 1999; 115(2):162-9. PubMed ID: 11830845
[No Abstract] [Full Text] [Related]
16. [Benign prostatic hyperplasia; recommendations for transmural care].
Göbel A
Ned Tijdschr Geneeskd; 1999 Feb; 143(6):327. PubMed ID: 10221091
[No Abstract] [Full Text] [Related]
17. Management of symptomatic benign prostatic hyperplasia--today.
Barkin J
Can J Urol; 2008 Dec; 15(6):4353-8. PubMed ID: 19046487
[TBL] [Abstract][Full Text] [Related]
18. Juvenile prostatic hyperplasia.
Choi YD; Cho NH; Kwon DH; Yang WJ; Oh YT; Choi SK
Urology; 2005 Oct; 66(4):881. PubMed ID: 16230167
[TBL] [Abstract][Full Text] [Related]
19. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level.
Punglia RS; D'Amico AV; Catalona WJ; Roehl KA; Kuntz KM
Cancer; 2006 Apr; 106(7):1507-13. PubMed ID: 16518812
[TBL] [Abstract][Full Text] [Related]
20. A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia.
Cannon GW; Mullins C; Lucia MS; Hayward SW; Lin V; Liu BC; Slawin K; Rubin MA; Getzenberg RH
J Urol; 2007 Feb; 177(2):610-4; discussion 614. PubMed ID: 17222644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
